Daniele Santini

2002–2025 年に発表

220
論文数
20,985
被引用数
85
h 指数
201
i10 指数

被引用数

Daniele Santini の年別被引用数1978 年: 被引用 1 件1996 年: 被引用 3 件1999 年: 被引用 2 件2002 年: 被引用 3 件2003 年: 被引用 6 件2004 年: 被引用 5 件2005 年: 被引用 17 件2006 年: 被引用 31 件2007 年: 被引用 43 件2008 年: 被引用 47 件2009 年: 被引用 83 件2010 年: 被引用 119 件2011 年: 被引用 162 件2012 年: 被引用 151 件2013 年: 被引用 117 件2014 年: 被引用 141 件2015 年: 被引用 136 件2016 年: 被引用 130 件2017 年: 被引用 137 件2018 年: 被引用 149 件2019 年: 被引用 592 件2020 年: 被引用 762 件2021 年: 被引用 924 件2022 年: 被引用 689 件2023 年: 被引用 523 件2024 年: 被引用 970 件2025 年: 被引用 492 件2026 年: 被引用 14 件1979〜1995 年は被引用が無いため表示していません1997〜1998 年は被引用が無いため表示していません2000〜2001 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 1,665 件、この内訳の 17.3%中国: 引用元論文 1,160 件、この内訳の 12.1%イタリア: 引用元論文 1,085 件、この内訳の 11.3%イギリス: 引用元論文 525 件、この内訳の 5.5%ドイツ: 引用元論文 456 件、この内訳の 4.7%フランス: 引用元論文 396 件、この内訳の 4.1%日本: 引用元論文 393 件、この内訳の 4.1%スペイン: 引用元論文 359 件、この内訳の 3.7%カナダ: 引用元論文 279 件、この内訳の 2.9%オーストラリア: 引用元論文 256 件、この内訳の 2.7%オランダ: 引用元論文 244 件、この内訳の 2.5%韓国: 引用元論文 195 件、この内訳の 2%
0%17.3%その他 27.1%

分野

  • Medicine72.1%
  • Biochemistry, Genetics and Molecular Biology18.9%
  • Immunology and Microbiology4.2%
  • Neuroscience0.7%
  • Engineering0.7%
  • Computer Science0.6%
  • その他2.8%

トピック

  • Cancer Immunotherapy and Biomarkers6.9%
  • Colorectal Cancer Treatments and Studies6.2%
  • Cancer Genomics and Diagnostics3.4%
  • Bone health and treatments3%
  • Genetic factors in colorectal cancer2.7%
  • Lung Cancer Treatments and Mutations2.6%
  • その他75.2%

共著者

全論文

検索で開く
  1. The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline

    著者: , , , , , , , , , , , , , , , - Annals of Oncology 2022 被引用: 480

  2. Bone health in cancer: ESMO Clinical Practice Guidelines

    著者: , , , , , , , , , , , , - Annals of Oncology 2020 被引用: 518

  3. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Camilla Qvortrup, Tine Plato Hansen, Eric Van Cutsem, Hubert Piessevaux, Diether Lambrechts, Mauro Delorenzi, Sabine Tejpar - The Lancet Oncology 2010 被引用: 2,143

  4. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan

    著者: , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2018 被引用: 420

  5. Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alessandro Inno, Federica Zoratto, Enzo Veltri, Barbara Di Cocco, Domenico Mallardo, Maria Grazia Vitale, David J. Pinato, Giampiero Porzio, Corrado Ficorella, Paolo A. Ascierto - Journal for ImmunoTherapy of Cancer 2020 被引用: 264

  6. Anxiety and depression in adult cancer patients: ESMO Clinical Practice Guideline

    著者: , , , , , , , , , , - ESMO Open 2023 被引用: 259

  7. Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2021 被引用: 185

  8. A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Rosa Rita Silva, Annagrazia Pireddu, Francesco Atzori, Rita Chiari, Biagio Ricciuti, Andrea De Giglio, Daniela Iacono, Alain Gelibter, Mario Occhipinti, Alessandro Parisi, Giampiero Porzio, Maria Concetta Fargnoli, Paolo A. Ascierto, Corrado Ficorella, Clara Natoli - Journal for ImmunoTherapy of Cancer 2019 被引用: 415

  9. Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples

    著者: , , , , , , , , , , , , , , - Journal of Experimental & Clinical Cancer Research 2020 被引用: 254

  10. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mario Roselli, Samanta Cupini, Serafina Mammoliti, Elisabetta Fenocchio, E. Corgna, Vittorina Zagonel, Gabriella Fontanini, Clara Ugolini, Luca Boni, Alfredo Falcone, Alfredo Falcone, Sara Lonardi, Filippo de Braud, Roberto Bordonaro, Evaristo Maiello, Emiliano Tamburini, Daniele Santini, Giovanni Luca Frassineti, Teresa Gamucci, Giuseppe Aprile, Alberto Zaniboni, Cristina Granetto, Angela Buonadonna, Francesco Di Costanzo, Gianluca Tomasello, Luca Gianni, Samantha Di Donato, Chiara Carlomagno, Matteo Clavarezza, Patrizia Racca, Andrea Mambrini, Mario Roselli, Giacomo Allegrini, Alberto Sobrero, Massimo Aglietta, E. Corgna, Enrico Cortesi, Domenico Corsi, Alberto Ballestrero, Andrea Bonetti, Francesco Clemente, Enzo Maria Ruggeri, Fortunato Ciardiello, Marco Benasso, S. Vitello, Saverio Cinieri, Stefania Mosconi, Nicola Silvestris, Antonio Frassoldati, S. Cupini, Alessandro Bertolini, Giampaolo Tortora, Carmelo Bengala, Daris Ferrari, Antonia Ardizzoia, Carlo Milandri, Silvana Chiara, Gianpiero Romano, Stefania Miraglia, Laura Scaltriti, Francesca Pucci, Livio Blasi, Silvia Brugnatelli, Luisa Fioretto, Angela Stefania Ribecco, Raffaella Longarini, M. Frisinghelli, Maria Banzi - The Lancet Oncology 2020 被引用: 325

  11. Classification of M1/M2-polarized human macrophages by label-free hyperspectral reflectance confocal microscopy and multivariate analysis

    著者: , , , , , , , , , , , - Scientific Reports 2017 被引用: 234

  12. Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Riccardo Marconcini, Maria Giuseppa Vitale, Linda Nicolardi, Rita Chiari, Michele Ghidini, Olga Nigro, Francesco Grossi, Michele De Tursi, Pietro Di Marino, Paola Queirolo, Sergio Bracarda, Serena Macrini, Alessandro Inno, Federica Zoratto, Enzo Veltri, Chiara Spoto, Maria Grazia Vitale, Katia Cannita, Alessandra Gennari, Daniel L. Morganstein, Domenico Mallardo, Lorenzo Nibid, Giovanna Sabarese, Leonardo Brunetti, Giuseppe Perrone, Paolo A. Ascierto, Corrado Ficorella, David J. Pinato - Clinical Cancer Research 2023 被引用: 74

  13. Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Maria Rita Migliorino, Giampiero Porzio, Katia Cannita, Corrado Ficorella, Sebastiano Buti - Clinical Lung Cancer 2019 被引用: 179

  14. Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Vincenzo Adamo - Advances in Therapy 2020 被引用: 168

  15. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Luigi Della Gravara, Alessandro Inno, De Tursi Michele, Antonino Grassadonia, Pietro Di Marino, Giovanni Mansueto, Federica Zoratto, Marco Filetti, Daniele Santini, Fabrizio Citarella, Marco Russano, Luca Cantini, Alessandro Tuzi, Paola Bordi, Gabriele Minuti, Lorenza Landi, Serena Ricciardi, Maria Rita Migliorino, Francesco Passiglia, Paolo Bironzo, Giulio Metro, Vincenzo Adamo, Alessandro Russo, Gian Paolo Spinelli, Giuseppe Luigi Banna, Alex Friedlaender, Alfredo Addeo, Katia Cannita, Corrado Ficorella, Giampiero Porzio, David J. Pinato - Journal for ImmunoTherapy of Cancer 2021 被引用: 144

  16. Tissue invasion and metastasis: Molecular, biological and clinical perspectives

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alan Bilsland, Dipita Bhakta-Guha, Dorota Halicka, Somaira Nowsheen, Francesco Pantano, Daniele Santini - Seminars in Cancer Biology 2015 被引用: 524

  17. Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Rossana Berardi, Anca Zgură, Giulia Mammone, Jawaher Ansari, Francesco Atzori, Rita Chiari, Aristotelis Bamias, Orazio Caffo, Giuseppe Procopio, Kaisa Sunela, Maria Bassanelli, Cinzia Ortega, Francesco Grillone, Johannes Landmesser, Michele Stanislaw Milella, Carlo Messina, Zsófia Kürönya, Alessandra Mosca, Dipen Bhuva, Daniele Santini, Nuno Vau, Franco Morelli, Lorena Incorvaia, Sara Elena Rebuzzi, Giandomenico Roviello, Andrey Soares, Renato Bisonni, Davide Bimbatti, Ignacio Ortego Zabalza, Alessandro Rizzo, Veronica Mollica, Giulia Sorgentoni, Fernando Sabino Marques Monteiro, Nicola Battelli, Sergio Bracarda, Camillo Porta - European Urology Oncology 2023 被引用: 77

  18. Insomnia in adult patients with cancer: ESMO Clinical Practice Guideline

    著者: , , , , , , , , , , , - ESMO Open 2023 被引用: 82

  19. Panitumumab Plus Trifluridine-Tipiracil as Anti–Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2023 被引用: 58

  20. Clinical application of bladder MRI and the Vesical Imaging-Reporting And Data System

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Nature Reviews Urology 2023 被引用: 34

  21. Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Marianna Tudini, Rosa Rita Silva, Annagrazia Pireddu, Francesco Atzori, Rita Chiari, Biagio Ricciuti, Daniela Iacono, Maria Rita Migliorino, Antônio Rossi, Giampiero Porzio, Katia Cannita, Valeria Ciciarelli, Maria Concetta Fargnoli, Paolo A. Ascierto, Corrado Ficorella - The Oncologist 2019 被引用: 221

  22. The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies

    著者: , , , , , , , , , , , , , , , , , , , , , - ESMO Open 2021 被引用: 102

  23. Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs)

    著者: , , , , , , , , , , , , , , - Cancer Treatment Reviews 2023 被引用: 51

  24. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?

    著者: , , , , , , , , , , , , , , , , , , - Annals of Oncology 2012 被引用: 213